This site is intended for Healthcare professionals only.

Novartis drug tops standard therapy in untreated lung cancer patients


Novartis drug tops standard therapy in untreated lung cancer patients

Novartis AG said its cancer drug, Zykadia, was twice as effective as standard chemotherapy in slowing the progression of a rare form of lung cancer in a late-stage study.

Patients with anaplastic lymphoma kinase-positive (ALK+) advanced non-small cell lung cancer treated with Zykadia had a median progression-free survival of 16.6 months, compared to 8.1 months for those on standard chemotherapy.

Overall survival data is still immature, but a positive trend in favor of Zykadia was observed, the Swiss drug maker said on Tuesday.

Zykadia has already secured accelerated approval in the United States as an alternative or second-line treatment in patients who have progressed on or cannot tolerate Pfizer’s Xalkori.

Zykadia also has conditional approval as a second-line treatment in Europe.



Source: Reuters
1 comment(s) on Novartis drug tops standard therapy in untreated lung cancer patients

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted